These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges.
    Author: Edwards DR.
    Journal: J Pathol; 2004 Apr; 202(4):391-4. PubMed ID: 15095265.
    Abstract:
    The tissue inhibitors of metalloproteinases (TIMPs) control the activities of matrix metalloproteinases (MMPs) and as such, they have been recognized as potential suppressors of angiogenesis and tumour invasion and metastasis. However, TIMP-3 has several unique properties that set it apart from other TIMPs, including its ability to bind to extracellular matrix, inhibit related adamalysin metalloproteinases (ADAMs), and induce apoptosis. New data suggest that high levels of TIMP-3 mRNAs in human breast tumours are associated with success of adjuvant endocrine therapy, but not chemotherapy.
    [Abstract] [Full Text] [Related] [New Search]